Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...
Overall, the trials showed that a once-monthly intravenous dose of anifrolumab was able to reduce disease activity across organ system in SLE, including skin and joints, and also helped patients ...
What it means: Right now, the common management of lupus involves suppressing the immune system ... participants anifrolumab, a drug that blocks interferon, prevented the T cell imbalance that ...
After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn ... Lupus is an autoimmune disease in which the immune system attacks healthy tissue in the body instead ...
THURSDAY, Feb. 20, 2025 (HealthDay News) -- For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks ...